Georgios Giamas

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

Opal Oncology Ltd. operates as a pharmaceutical company. It develops drugs for cancer. The company was founded in 2012 and is headquartered in Cambridge, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Five Alarm Bio Ltd. is a drug discovery firm that develops compounds that boost bodies’ ability to defend self against the damage of aging. It focuses on novel approaches to anti-aging, with broad potential therapeutic application. The company was founded by William Arthur Bains, Sunil Rajen Shah, and Ann Baker in 2016 and is headquartered in Cambridge, the United Kingdom.

Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

Oxford Drug Design Ltd. develops application of new technologies to drive computer-aided drug discovery. It specializes in drug discovery, molecular modeling, lead identification and optimisation, formulation modeling and preclinical studies. The company was founded by W. Graham Richards in 2001 and is headquartered in Oxford, the United Kingdom.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.